The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 36 | — | 20.1x | Near average | |
Growth | 44 | -27.8% | 5.6% | Near average | |
Quality | 35 | 709.6% | 7.6% | Near average | |
Safety | 41 | 0.2x | 0.4x | Near average | |
Capital Return | 19 | — | 2.19% | Below average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Inhibrx Biosciences, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Inhibrx Biosciences, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
The price forecast analysis for INBX shows a state of complete stability in the target price at $325, representing a significant premium compared to the current price ($101.32). However, caution is advised as this consensus results from the coverage of only one analyst, meaning there is zero dispersion and an absence of multiple perspectives, which increases concentration risk in the estimate.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.